镰状细胞病异基因造血干细胞移植或基因治疗后的血液流变学
该研究评估了69例镰状细胞病患者(43例接受异基因造血干细胞移植,11例接受基因治疗)共123份血样的流变学参数,并与15例羟基脲 optimal 应答者比较。结果显示,接受镰状细胞特质供者移植者的流变学参数优于基因治疗组和羟基脲组,而基因治疗组与羟基脲组相当。提示流变学检测或可纳入移植和基因治疗后的随访。
要点
- 镰状细胞特质供者移植后流变学参数优于基因治疗和羟基脲 optimal 组。
- 基因治疗与羟基脲 optimal 组的流变学结果相当。
- 流变学异常常见,或可纳入移植和基因治疗后的随访检测。
核心结论
- 接受镰状细胞特质供者移植者的流变学参数优于基因治疗组和羟基脲 optimal 组,基因治疗组与羟基脲 optimal 组相当。
研究设计与样本
- 研究评估了69例患者的123份血样,其中43例接受异基因造血干细胞移植(32例匹配相关供者,11例单倍体供者),11例接受基因治疗。
- 结果与15例羟基脲 optimal 胎儿血红蛋白应答者进行比较。
主要发现
- 镰状细胞特质供者移植组中位EImin为0.6,基因治疗组为0.31,羟基脲 optimal 组为0.15。
- 镰状细胞特质供者移植组中位PoS为0,基因治疗组为26.21,羟基脲 optimal 组为36.2。
- 镰状细胞特质供者移植组中位致密红细胞百分比为0.9,羟基脲 optimal 组为4.9,所有比较P< .05。
- 基因治疗组与羟基脲 optimal 组流变学结果相当(P> .05)。
临床怎么用
- 鉴于流变学异常患者比例较高且流变学与镰状细胞病相关并发症相关,可考虑将流变学检测纳入移植和基因治疗后的随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Allogeneic hematopoietic cell transplantation (HCT) and autologous hematopoietic stem cell-based gene therapies are potentially curative for sickle cell disease (SCD). Although most patients experience resolution of overt clinical symptoms associated with SCD with donor-dominant myeloid chimerism after undergoing HCT or the induction of a substantial amount of alternative hemoglobin (Hb) after gene therapy (GT), whether the underlying subclinical physiology is normalized in these individuals is unknown. One approach to evaluating the underlying physiology is to characterize the blood rheology of patients after they receive these therapies. We assessed the rheology of 123 blood samples from 69 patients, of whom 43 underwent HCT (32 from matched related donors; 11 from haploidentical donors) and 11 received GT. The results were compared to those for patients treated with hydroxyurea with optimum fetal Hb response (HUOptimum; n = 15). Median rheology parameters of recipients of HCT from donors with sickle cell trait (HbAS) were superior to those of GT recipients (elongation index under hypoxia [EImin]: 0.6 vs 0.31; point of sickling [PoS]: 0 vs 26.21) and of the HUOptimum cohort (EImin, 0.6 vs 0.15; PoS, 0 vs 36.2; percentage of dense red blood cells, 0.9 vs 4.9; P< .05 for all comparisons). Results for the GT and HUOptimum groups were comparable (P> .05). Given the substantial number of patients with abnormal rheology and the associations between rheology and SCD-related complications, rheology tests may be included in the follow-up care for HCT and GT recipients.
引用
- Patel AP, John TD, Gottschalk S, et al. Blood rheology after allogeneic hematopoietic stem cell transplantation or gene therapy in sickle cell disease. Blood Adv. 2026. PMID: 42448317. doi:10.1182/bloodadvances.2026020768
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。